ArticleScientific reports2021

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

Sander A L Palit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.